Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

Administration (FDA) to include these data in the prescribing information in the U.S.

Pharmion is also developing a next generation product, oral Azacitidine, for the treatment of MDS and other cancers where demethylation can provide an anti-tumor effect. Oral Azacitidine is the subject of a Phase 1 multi-center, open label dose escalation trial that will assess the maximum tolerated dose, dose limiting toxicities and safety of a seven day, multi-cycle oral dosing regimen of oral Azacitidine in patients with MDS and AML. In addition, the trial will examine pharmacokinetics and pharmacodynamic effects of orally administered Azacitidine, as compared with parenteral Vidaza.

Pharmion will hold a conference call to discuss these results later this morning, August 2, at 9:00 a.m. ET. The conference call will be simultaneously webcast on the Company's web site at http://www.pharmion.com, and archived for future review. Dial-in numbers for the conference call for institutional investors and analysts are as follows: participants from the U.S. 866.314.5232, International participants 617.213.8052, passcode: 71992680.

About the Trial Design

This was the largest randomized study ever conducted in higher-risk MDS. The study was a multi-center, randomized, open-label, parallel-group, Phase 3 trial of subcutaneous (SC) Vidaza (administered at 75/mg/m2/day SC for seven consecutive days every 28 days) plus best supportive care versus CCR plus best supportive care for the treatment of MDS. CCR consisted of one of three physician selected regimens: best supportive care alone, low-dose cytarabine plus best supportive care or standard chemotherapy plus best supportive care. EPO and prophylactic G-CSF use was not permitted. The CCR represented standard of care within the territories where the trial was conducted. The study evaluated 358 higher-risk MDS patients at sites in the U.S., Europe and Australia. Patients
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

3

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...BRUNSWICK,N.J.,Nov.25/PRNewswire/--SwissrayInterna...ography( ddR )systems,announcedtodaythatitsoperati...gtermviewtowardsgrowingSwissray,smedicalimagingbra...roperty,aswellascontractsandinventory.After25years...xtleveloftechnologicaladvancementswithstableandste...
(Date:11/25/2009)...IEGO,Nov.25/PRNewswire-FirstCall/--NuVasive,Inc.(N...pingproductsforminimallydisruptivesurgicaltreatmen...ncecallonMonday,November30,2009,at5:30p.m.ET/2:30p...ativetoreimbursementfortheCompany,sproductsandwill...ionandanswersession.Thedial-innumbersare1-877-407-...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/--Reportlinker.comannouncest...ue: ,, PainManagement-GlobalTrends ,, h...t---Global-Trends.html ,, Widespreadavailabili...andtheadventofnewdrugshaveacceleratedthepaceofgrow...imbursementstructurecontinuetoshapedemandforservic...
Breaking Medicine Technology:Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Newly Updated Pharmacy State Law Compendium Available 5335 1Newly Updated Pharmacy State Law Compendium Available 5335 2Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 1Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 2Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 3CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 1CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 2CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 3
... - Cytogen,Corporation (NASDAQ: CYTO) today announ...shed at upcoming major medical meetings. The,data ...QUADRAMET(R),(samarium Sm-153 lexidronam injection...astatic bone disease arising from prostate,cancer ...,evaluating the outcomes of prostate cancer patien...
...-- Once-daily,dosing with Otsuka,s investigational... antagonist, was associated with improvements,in s...ailure (ADHF),in hospitalized patients receiving c...ir long-term survival versus placebo.(1) These,dat...e,international landmark trial Efficacy of Vasopre...
Other Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
(Date:11/26/2009)... Fans get a bigger thrill when on an emotional rol...v. 26 (HealthDay News) -- Call it the fear factor ...ggests that spectators -- especially those who roo...faction if it,s a closely contested match and vict...even despair. , Chew on that this Thanksgiving ...
(Date:11/26/2009)..., Research Triangle Denta...entral North Carolina, today announced the expansi...fied LUMINEER Dentist, Dr. Doug Macmillan. , ...rch Triangle Dental is pleased to announce that Dr...st, recently completed an additional advanced trai...
(Date:11/25/2009)...,, EDINA,Minn.,Nov.25/PRNewswire-USNewswire/...dentist.Butachiropractorcanalsogivepatientsthehelp...hichiswhereyourjaw(mandible)contacts/connectswithy...sassociatedwithTMJdysfunctionarepainwithchewing,cl...ausedfromTMJdysfunctionincluding:headaches,fatigue...
(Date:11/25/2009)...,, TORONTOandCALGARY,Nov.25/PRNewswire/-Sent...sonanceImaging(MRI)coilsandsoftwareandCalgaryScien...logies,haveintroducedawebversionofAegis(TM)Breast4...veinterfaceisthefirsttrulyzero-footprintWebclientb...tific,sPureWeb(TM)platformallowsforzero-footprinta...
(Date:11/25/2009)...,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNews...FDA,sCenterforDrugEvaluationandResearch,titled"ADi...,"appearsintheNov.26,2009issueofTheNewEnglandJourn...cgi-bin/prnh/20090824/FDALOGO ) ,, Inthearticle...naccesstopainmedicationforthosewhoneeditandmanagin...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...search Network is very near to achieving one of to...ge in the best possible health conditions.// ...nish universities of Seville, Oviedo, Saragossa, B...beings and present in many types of food – delays ...
...ev has launched a seven-day camp in this Taj Mahal...on sex and other licentious activities.// Ram...d, said he was opposed to sex education being give...vised the young to 'exercise restraint' rather tha...
... polluted river and a handful of concerned citizen...heralded World Earth Day Sunday, //by raising its ...ile ecosystem. 'We are on the brink of a cha... needs to be addressed immediately and a day such ...
...a massive immunization drive aimed at protecting m...eak. According to health experts, nearly 10% of th... Iraq's Ministry of Health is conducting the...ld Health Organization and UNICEF have got togethe...
... the US has sentenced a man to prison for conceali...to a plasma collection center at Hammond.// ...o selling blood contaminated with the HIV in Septe...a is the largest single component of blood, making...
...as combined nanotechnology and biology to enable t...rly results. Dr. Samuel is the director of the Ins...western University. He suggests that nanotechnolog...logy might achieve in regenerative medicine, paral...
Other Medicine News:Health News:High Melatonin can Help Delay Ageing 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2Health News:Nanotechnology Could Treat Spinal Cord Injuries, Diabetes, and Parkinson's Disease 2
... Touch control panel with 3 charging wells. Availa...Blue and Cinnamon. Spring balanced refractor and s...ction for lifelong quality. Sealed hydraulic syste...ement. Chair back reclines manually to fully horiz...
...eveloped the patented HydroKeratome corneal cuttin...t and industry experts believe it will replace the...okeratome, currently used in the LASIK refractive ...Company has demonstrated that its proprietary tech...
2.5v Ophthalmoscope Set
3.5v Coaxial Ophthalmoscope Set
Medicine Products: